̳

411 on PCSK9 Inhibitors

— How effective are they at lowering cholesterol?

MedpageToday

, a resident physician at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, produces a podcast on cardiology issues. Here, he and a colleague discussed the expensive new PCSK9 inhibitors for treating patients with stubbornly high LDL cholesterol. Perry's previous podcast on ̳ addressed the future of percutaneous interventions in the wake of the ORBITA trial.